Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CPhI South East Asia to Expand to Thailand | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

CPhI South East Asia to Expand to Thailand

From 2019 onwards it will alternate its annual location between Indonesia and Thailand

By: Betsy Louda

, Contract Pharma

CPhI South East Asia, organized by UBM, has announced that from 2019 onwards it will alternate its annual location between the region’s two largest pharma economies, Indonesia and Thailand.

 

In 2019, CPhI South East Asia will take place at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand (March 12-14) before returning to Jakarta International Expo (JIExpo) in Indonesia in 2020 (March 4-6). CPhI South East Asia’s strategic move to Thailand will further strengthen the event’s appeal within the region. Organizers’ anticipate a significant growth in new visitors from more diverse locations with the new venue, catering to attendees that were previously unable to participate.

 

The event’s first visit to Thailand comes at a significant time for the country, as pharma sales are expected to grow by 8.4% in 2019, with multinational corporations increasingly looking to partner with local contract manufacturers in order to expedite and streamline market access. According to data from BMI Research, by 2021 the pharmaceutical market is forecast to reach a value of THB209.7bn ($6.3B), experiencing a compound annual growth rate (CAGR) of 5.4% in local currency terms and 6.8% in US dollar terms. Over the extended forecast period, medicine sales will experience a 10-year CAGR of 5.5% and 6.3% in local currency and US dollar terms respectively, reaching THB275.2bn (USD8.4bn) by 2026.

 

“This is very much a natural progression for the CPhI South East Asia and the region, opening even greater opportunities to meet new partners and expand pharma sales. Collectively, these two countries account for over 50% of the region’s sales. Our research shows there is large opportunity, in particular, for contract services and ingredients, and by annually switching location we will increase the depth and quality of regional partners available. Not to mention, we attract a wider perspective of visitors, all of which will ultimately accelerateASEAN’s Pharmaceutical harmonisation and cross-border collaborations.” said Chris Kilbee, group director, Pharma at UBM.

 

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters